Plain-English translation of NCT06556199 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a clinical trial testing whether , when combined with two other medications ( and an anti-PD-1 antibody), can safely treat primary central nervous system lymphoma—a type of cancer that starts in the brain—in patients whose cancer has returned or stopped responding to previous treatment. The trial will first test increasing doses of the medication combination to find the safest dose, then expand to more patients to see how well this treatment works.
Brain lymphoma that comes back or doesn't respond to standard treatment is very difficult to manage, and patients have limited options. This trial explores whether combining this medication with two other drugs might give patients a better chance at controlling their disease.
You likely qualify if…
You likely don't qualify if…
You will take the medication combination by mouth for 6 cycles of treatment (each cycle lasts several weeks). You'll have regular hospital visits for blood tests, MRI or CT scans, and possibly lumbar punctures (spinal taps) to monitor how well the treatment is working and check for side effects. If your cancer responds well, you may continue receiving one of the medications as maintenance therapy to help prevent the cancer from coming back until your disease progresses, you experience unmanageable side effects, or you choose to stop.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China